Maja Theresa Dieterlen

TL;DR: It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients.

TL;DR: In this article, the status of personalized treatment with mycophenolic acid (MPA) is discussed, including the criteria for analytics, methods to estimate exposure including pharmacometrics, potential influence of pharmacogenetics, development of biomarkers, and the practical aspects of implementation of target concentration intervention.

TL;DR: It is found that SDF1 stimulates proliferation and induces migration of C2C12 cells with a potency similar to that of FGF2 and HGF, which both represent prototypical extracellular regulators of myogenesis.

TL;DR: Outcomes from this large single-center cohort at increased surgical risk demonstrate excellent long-term durability of the Trifecta valve for SAVR and feasibility of treating SVD by V-in-V TAVI.

TL;DR: Clinical relevance of monitoring the activity of inosine-5′-monophosphate dehydrogenase (IMPDH), the target enzyme of mycophenolic acid, and of the phosphorylation of mechanistic target of rapamycin (mTOR) molecules is discussed.